Circulating Plasma Cell-free DNA (cfDNA) As a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in Head and Neck Cancer

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2023 Sep 6

PMID 37671311

Authors

Michael I Koukourakis

Erasmia Xanthopoulou

Ioannis M Koukourakis

Sotirios P Fortis

Nikolaos Kesesidis

Ioannis Karakasiliotis

Constantin N Baxevanis

Affiliations

Soon will be listed here.

Abstract

Background/aim: The plasma levels of cell-free DNA (cfDNA) in cancer patients increase due to rapid cancer cell proliferation and death. Therefore, cfDNA can be used to study specific tumor-DNA features. In addition, the non-specific cfDNA concentration may be an important biomarker of cancer prognosis.

Patients And Methods: We prospectively examined the predictive role of cfDNA levels and the kinetics in the outcome of chemo-radiotherapy (CRT) in a cohort of 47 patients with locally advanced squamous cell head-neck cancer (SCHNC) treated with definitive chemo-radiotherapy.

Results: Increased cfDNA levels after therapy completion (after/before treatment ratio; A/B-ratio >1) were found in 26/47 patients (55.3%). Locally advanced T4-stage was significantly associated with higher cfDNA levels after CRT (3.3 ng/μl in T4-stage vs. 1.3 ng/μl in T1-3 stages, p=0.007). Patients who responded to CRT (partial/complete response) had significantly lower cfDNA levels before therapy (mean values 1.2 ng/μl vs. 2.7 ng/μl, p=0.03). A significantly worse locoregional progression-free survival in patients with an A/B-ratio >1 was documented (p=0.01; hazard ratio 3.5, 95%CI=1.2-9.7). This was also confirmed in multivariate analysis, where the A/B-ratio was an independent predictive variable of locoregional relapse (p=0.03, hazard ratio 3.9, 95%CI=1.2-13).

Conclusion: High post-CRT cfDNA levels could be an early biomarker for the immediate recruitment of patients with SCHNC in consolidation chemo-immunotherapy protocols.

Citing Articles

Application of Z-scan technique in detecting circulating free DNA for prostate cancer diagnosis and monitoring.

Alves S, Junior C, Muniz G, Silva L, Zortea R, Lima V Lasers Med Sci. 2025; 40(1):114.

PMID: 39984815 DOI: 10.1007/s10103-025-04357-3.

Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC.

Tosello V, Grassi A, Rose D, Bao L, Zulato E, Dalle Fratte C Sci Rep. 2024; 14(1):18545.

PMID: 39122833 PMC: 11316016. DOI: 10.1038/s41598-024-68229-6.

Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head-Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay.

Koukourakis M, Xanthopoulou E, Koukourakis I, Fortis S, Kesesidis N, Kakouratos C Curr Oncol. 2023; 30(10):8902-8915.

PMID: 37887543 PMC: 10604986. DOI: 10.3390/curroncol30100643.

References

Chen E, Cario C, Leong L, Lopez K, Marquez C, Chu C . Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021; 11(1):5040. PMC: 7930042. DOI: 10.1038/s41598-021-84507-z. View

Muhanna N, Eu D, Chan H, Douglas C, Townson J, Di Grappa M . Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy. BMC Cancer. 2021; 21(1):1075. PMC: 8487588. DOI: 10.1186/s12885-021-08791-8. View

Leon S, Shapiro B, SKLAROFF D, Yaros M . Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3):646-50. View

Koukourakis M, Giatromanolaki A . Tumor microenvironment, immune response and post-radiotherapy tumor clearance. Clin Transl Oncol. 2020; 22(12):2196-2205. DOI: 10.1007/s12094-020-02378-8. View

Garavello W, Ciardo A, Spreafico R, Gaini R . Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006; 132(7):762-6. DOI: 10.1001/archotol.132.7.762. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Grabuschnig S, Bronkhorst A, Holdenrieder S, Rosales Rodriguez I, Schliep K, Schwendenwein D . Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. Int J Mol Sci. 2020; 21(21). PMC: 7662960. DOI: 10.3390/ijms21218062. View

Verma T, Kumari S, Mishra S, Rastogi M, Tiwari V, Agarwal G . Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma. Indian J Pathol Microbiol. 2020; 63(4):521-526. DOI: 10.4103/IJPM.IJPM_28_20. View

Koukourakis I, Papadimitriou M, Desse D, Zygogianni A, Papadimitriou C, Koukourakis M . Is anti-PD-1 immunotherapy a means for post-irradiation tumor clearance in head and neck cancer?. Med Oncol. 2022; 39(12):186. DOI: 10.1007/s12032-022-01778-w. View

10.

Mazurek A, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, Skladowski K . Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 2016; 54:36-41. DOI: 10.1016/j.oraloncology.2015.12.002. View

11.

Li B, Drilon A, Johnson M, Hsu M, Sima C, Mcginn C . A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Ann Oncol. 2015; 27(1):154-9. PMC: 4684155. DOI: 10.1093/annonc/mdv498. View

12.

Zhong Y, Fan Q, Zhou Z, Wang Y, He K, Lu J . Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer. Cancer Manag Res. 2020; 12:3099-3106. PMC: 7211302. DOI: 10.2147/CMAR.S243320. View

13.

Christenson E, Lim S, Durham J, De Jesus-Acosta A, Bever K, Laheru D . Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Res Commun. 2023; 2(11):1418-1425. PMC: 10035498. DOI: 10.1158/2767-9764.CRC-22-0343. View

14.

Tissot C, Toffart A, Villar S, Souquet P, Merle P, Moro-Sibilot D . Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015; 46(6):1773-80. DOI: 10.1183/13993003.00676-2015. View

15.

Bortolin M, Tedeschi R, Bidoli E, Furlan C, Basaglia G, Minatel E . Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy. Biomarkers. 2015; 20(6-7):422-8. DOI: 10.3109/1354750X.2015.1094139. View

16.

Adusei E, Ahenkorah J, Adu-Aryee N, Adutwum-Ofosu K, Tagoe E, Koney N . Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients. Med Sci (Basel). 2021; 9(2). PMC: 8163010. DOI: 10.3390/medsci9020037. View

17.

Malusecka E, Giglok M, Suwinski R, Rutkowski T, Mazurek A . Quantitative analysis of plasma DNA in anal cancer patients. Contemp Oncol (Pozn). 2022; 26(2):128-132. PMC: 9319180. DOI: 10.5114/wo.2022.118132. View

18.

Rumore P, Steinman C . Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest. 1990; 86(1):69-74. PMC: 296691. DOI: 10.1172/JCI114716. View

19.

Peled M, Agassi R, Czeiger D, Ariad S, Riff R, Rosenthal M . Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer. Sci Rep. 2020; 10(1):14601. PMC: 7471679. DOI: 10.1038/s41598-020-71357-4. View

20.

Yan Y, Guo Q, Wang F, Adhikari R, Zhu Z, Zhang H . Cell-Free DNA: Hope and Potential Application in Cancer. Front Cell Dev Biol. 2021; 9:639233. PMC: 7938321. DOI: 10.3389/fcell.2021.639233. View